Cefazolin versus placebo for surgical antibiotic prophylaxis in low-risk cesarean delivery: a feasibility blinded randomized controlled trial.

Victoria A Eley, Jason Roberts, Elizabeth Martin, Severine Navarro, Akwasi Amoako, Leonie Callaway, Jeffrey Lipman, Gunter Hartel, Mimi Tang, Yan Lu, Christine Woods

Journal: BMC pregnancy and childbirth 2025;25(1):353

PMID: 40140987

Abstract

BACKGROUND

Pre-incisional antibiotics are recommended for all patients having cesarean delivery, despite emerging concerns regarding effects on the infant. In this feasibility blinded randomized controlled trial we aimed to test research processes in low-risk women receiving cefazolin or placebo prior to elective cesarean delivery.

METHODS

The trial was prospectively registered (ACTRN12619001705178). Eligible women were aged ≥ 18 and < 40 years, ≥ 37 weeks gestation, at low risk of surgical site infection (SSI) and recruited from a single tertiary centre. We reported proportions of women eligible and consenting; adherence to perioperative infection prevention; blinding adequacy of staff using Bang's blinding index; SSI surveillance and diagnosis according to the Centre for Disease Control definitions and patient reported outcome measures using validated questionnaires up to 90 days.

RESULTS

We screened 1651 women, with 1245 (75%) ineligible based on body mass index or presence of diabetes. Of 287 eligible women, 30 were randomized (11%) with 15 in each group. Reasons for non-participation included "wanting antibiotics" (68, 27%), "no reason" (62, 25%) and lack of research staff (33, 13%). Compliance with perioperative infection prevention occurred in 5 of 7 steps. Spontaneous placental separation occurred in 25 (83%) and Comfeel dressing in 29 (97%). Blinding was adequate for all staff groups. SSI surveillance occurred in 156 of 210 (74%) timepoints. SSI occurred in two patients who received pre-incisional cefazolin and were successfully treated as outpatients. Patient reported outcome questionnaires were completed at 136 of 180 (76%) timepoints. There was no difference in maternal health-related quality of life between the groups.

CONCLUSIONS

Feasibility was impacted by the high-risk population and patient desire for antibiotics. Adherence to perioperative infection prevention practices were high but incomplete. These study processes could be effectively applied in a larger population, targeting low risk maternity patients.

TRIAL REGISTRATION

Prospectively registered 4/12/2019 with the Australian New Zealand Clinical Trials Registry (ACTRN12619001705178).

© 2025. The Author(s).

Address: Department of Anaesthesia and Perioperative Medicine, The Royal Brisbane and Women's Hospital, Butterfield St, Herston, Brisbane, 4006, Queensland, Australia. [email protected].; Medical School, Faculty of Medicine, The University of Queensland, St Lucia 4067, Brisbane, QLD, Australia. [email protected].; Mucosal Immunology, QIMR Berghofer Medical Research Institute, Herston, Brisbane, 4006, Australia.; Centre for Childhood Nutrition Research, Queensland University of Technology, Brisbane, Australia.; Wesley Research Institute, Auchenflower, Queensland, 4066, Australia.; Mater Research Institute, The University of Queensland, South Brisbane 4101, Brisbane, QLD, Australia.; Medical School, Faculty of Medicine, The University of Queensland, St Lucia 4067, Brisbane, QLD, Australia.; Women's and Newborns Services, The Royal Brisbane and Women's Hospital, Butterfield St, Herston, QLD, 4006, Australia.; Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, 4006, Australia.; School of Public Health, The University of Queensland, Brisbane, QLD, Australia.; Department of Anaesthesia and Perioperative Medicine, The Royal Brisbane and Women's Hospital, Butterfield St, Herston, Brisbane, 4006, Queensland, Australia.; Medical School, Faculty of Medicine, The University of Queensland, St Lucia 4067, Brisbane, QLD, Australia.; Medical School, Faculty of Medicine, The University of Queensland, St Lucia 4067, Brisbane, QLD, Australia.; Jamieson Trauma Institute, The University of Queensland, St Lucia 4067, Brisbane, QLD, Australia.; Nimes University Hospital, University of Montpellier, Nimes, France.; Centre for Clinical Research, Faculty of Medicine, University of Queensland, The University of Queensland, Brisbane, Australia.; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, 4006, Australia.; Allergy Immunology, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.; Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.